Preparation and characterization of drug-LHRH conjugates

SE S. C. Eluu
JO J. D. Obayemi
AS A. A. Salifu
DY D. Yiporo
AO A. O. Oko
TA T. Aina
JO J. C. Oparah
CE C. C. Ezeala
PE P. O. Etinosa
CU C. M. Ugwu
CE C. O. Esimone
WS W. O. Soboyejo
request Request a Protocol
ask Ask a question
Favorite

Prodigiosin and paclitaxel were conjugated separately to Luteinizing Hormone-Releasing Hormone (LHRH) for the specific targeting and treatment of triple negative breast cancer (TNBC), as described in previous work111.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A